Project

The key details about the PurHumanDrome project based on the grant agreement:

Project Overview:

Project number: 101182530
Project name: Disrupting purine de novo biosynthesis to fight cancer – from molecules to cells to in vivo studies
Project acronym: PurHumanDrome
Project duration: 48 months (1 November 2024 – 31 October 2028r.)

Participants:

Coordinator:
- UNIWERSYTET OPOLSKI (UO), Poland
Beneficiaries:
- CONSIGLIO NAZIONALE DELLE RICERCHE (CNR), Italy
- YEREVAN STATE UNIVERSITY FOUNDATION (YSU), Armenia
Associated Partners:
- ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (RMIT), Australia
- COASTAL CAROLINA UNIVERSITY (CCU), USA

Project Summary:

This project aims to find a specific inhibitor for the ATIC enzyme involved in de novo purine biosynthesis to fight cancer. It combines expertise from scientists in 5 countries across 3 continents, applying knowledge from biology, chemistry, bioinformatics, biophysics and medicine. The research will evaluate new peptide-like compounds for inhibiting ATIC enzyme dimerization, with studies in cancer cell lines and Drosophila flies.

Key Objectives:

Develop new peptide-like compounds as potential ATIC inhibitors
Evaluate efficacy of compounds in inhibiting ATIC dimerization
Conduct studies in cancer cell lines and Drosophila models
Provide new insights into cancer metabolic pathways
Foster international collaboration and knowledge exchange

Expected Benefits:

Improve cancer treatment approaches
Advance understanding of cancer metabolism
Train young scientists in interdisciplinary research
Establish new international collaborations
Enhance communication skills of European scientists

The project combines cutting-edge research with capacity building to make progress against cancer while developing the next generation of cancer researchers.